Javascript must be enabled to continue!
Risk of Recurrent Adverse Outcomes in Gestational Diabetes: a Retrospective Cohort Study
View through CrossRef
Objective: Compare the risk of recurrent adverse delivery outcome (ADO)
or adverse neonatal outcome (ANO) between consecutive gestational
diabetes (GDM) pregnancies. Design: Retrospective cohort Setting:
Sydney, Australia Population or Sample: 424 pairs of consecutive
singleton GDM pregnancies, 2003-2015 Main Outcome Measures:. ADO:
instrumental delivery and emergency Caesarean. ANO: large for
gestational age (LGA), small for gestational age (SGA), and composite
ANO (LGA/SGA/stillbirth/neonatal death/shoulder dystocia). Methods:
Using each pregnancy pair (“index” and “subsequent” pregnancy), we
calculated ADO and ANO rates and determined risk factors for subsequent
pregnancy outcomes (multivariate regression). Results: Subsequent
pregnancies had higher rates of elective Caesarean (30.4% vs 17.0%,
p<0.001) and lower rates of instrumental delivery (5% vs
13.9%, p<0.001), emergency Caesarean (7.1% vs 16.3%,
p<0.001) and vaginal delivery (62.3% vs 66.3%, p=0.01). ANO
rates in index and subsequent pregnancies did not differ. Index
pregnancy adverse outcome was associated with a higher risk of repeat
outcome: RR 3.09 (95%CI:1.30, 7.34) for instrumental delivery, RR 2.20
(95%CI:1.06, 4.61) for emergency Caesarean, RR 4.55 (95%CI:3.03, 6.82)
for LGA, RR 5.01 (95%CI:2.73, 9.22) for SGA and RR 2.10 (95%CI:1.53,
2.87) for composite ANO). The greatest risk factor for subsequent LGA
(RR 3.13 (95%CI:2.20, 4.47)), SGA (RR 4.71 (95%CI:2.66, 8.36)) or
composite ANO (RR 2.01 (95%CI:1.46, 2.78)) was having the same outcome
in the index pregnancy. Conclusions: Women with GDM and an adverse
outcome are at very high risk of the same complication in their
subsequent GDM pregnancy, representing a high-risk group that should be
targeted for directed management over routine care.
Title: Risk of Recurrent Adverse Outcomes in Gestational Diabetes: a Retrospective Cohort Study
Description:
Objective: Compare the risk of recurrent adverse delivery outcome (ADO)
or adverse neonatal outcome (ANO) between consecutive gestational
diabetes (GDM) pregnancies.
Design: Retrospective cohort Setting:
Sydney, Australia Population or Sample: 424 pairs of consecutive
singleton GDM pregnancies, 2003-2015 Main Outcome Measures:.
ADO:
instrumental delivery and emergency Caesarean.
ANO: large for
gestational age (LGA), small for gestational age (SGA), and composite
ANO (LGA/SGA/stillbirth/neonatal death/shoulder dystocia).
Methods:
Using each pregnancy pair (“index” and “subsequent” pregnancy), we
calculated ADO and ANO rates and determined risk factors for subsequent
pregnancy outcomes (multivariate regression).
Results: Subsequent
pregnancies had higher rates of elective Caesarean (30.
4% vs 17.
0%,
p<0.
001) and lower rates of instrumental delivery (5% vs
13.
9%, p<0.
001), emergency Caesarean (7.
1% vs 16.
3%,
p<0.
001) and vaginal delivery (62.
3% vs 66.
3%, p=0.
01).
ANO
rates in index and subsequent pregnancies did not differ.
Index
pregnancy adverse outcome was associated with a higher risk of repeat
outcome: RR 3.
09 (95%CI:1.
30, 7.
34) for instrumental delivery, RR 2.
20
(95%CI:1.
06, 4.
61) for emergency Caesarean, RR 4.
55 (95%CI:3.
03, 6.
82)
for LGA, RR 5.
01 (95%CI:2.
73, 9.
22) for SGA and RR 2.
10 (95%CI:1.
53,
2.
87) for composite ANO).
The greatest risk factor for subsequent LGA
(RR 3.
13 (95%CI:2.
20, 4.
47)), SGA (RR 4.
71 (95%CI:2.
66, 8.
36)) or
composite ANO (RR 2.
01 (95%CI:1.
46, 2.
78)) was having the same outcome
in the index pregnancy.
Conclusions: Women with GDM and an adverse
outcome are at very high risk of the same complication in their
subsequent GDM pregnancy, representing a high-risk group that should be
targeted for directed management over routine care.
Related Results
Gestational Glucose Intolerance and Risk of Future Diabetes
Gestational Glucose Intolerance and Risk of Future Diabetes
<p> </p>
<p><strong>Objective:</strong> Pregnant individuals are universally screened for gestational diabetes. Gestational glucose intolerance (GGI,...
Gestational Glucose Intolerance and Risk of Future Diabetes
Gestational Glucose Intolerance and Risk of Future Diabetes
<p> </p>
<p><strong>Objective:</strong> Pregnant individuals are universally screened for gestational diabetes. Gestational glucose intolerance (GGI,...
Prenatal Physical Activity, Pre-Pregnancy BMI, and Their Relationship with Gestational Diabetes: A Retrospective-Prospective Single-Center Study
Prenatal Physical Activity, Pre-Pregnancy BMI, and Their Relationship with Gestational Diabetes: A Retrospective-Prospective Single-Center Study
Background: In recent years, there has been an increase in the incidence of gestational diabetes (GDM) with serious risks for both mother and child. Pre-pregnancy BMI and physical ...
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Abstract
Introduction
Tarlatamab is a Delta-like ligand 3 (DLL3) -directed bispecific T-cell engager recently approved for use in patients with advanced small cell lung cancer (SCL...
Adverse Pregnancy Outcomes and Long-Term Risk of Atrial Fibrillation
Adverse Pregnancy Outcomes and Long-Term Risk of Atrial Fibrillation
Importance
Women with adverse pregnancy outcomes have higher subsequent cardiovascular risks, but their long-term risk of atrial fibrillation (AF) and potential...
A Multi-Polygenic Risk Score Approach Incorporating Physical Activity Genotypes for Predicting Type 2 Diabetes and Associated Comorbidities: A FinnGen Study
A Multi-Polygenic Risk Score Approach Incorporating Physical Activity Genotypes for Predicting Type 2 Diabetes and Associated Comorbidities: A FinnGen Study
ABSTRACT
Aims/hypothesis
Genetic prediction of type 2 diabetes risk has proven difficult using current methods. Recent studies ...
Pembrolizumab and Sarcoma: A meta-analysis
Pembrolizumab and Sarcoma: A meta-analysis
Abstract
Introduction: Pembrolizumab is a monoclonal antibody that promotes antitumor immunity. This study presents a systematic review and meta-analysis of the efficacy and safety...
Microwave Ablation with or Without Chemotherapy in Management of Non-Small Cell Lung Cancer: A Systematic Review
Microwave Ablation with or Without Chemotherapy in Management of Non-Small Cell Lung Cancer: A Systematic Review
Abstract
Introduction
Microwave ablation (MWA) has emerged as a minimally invasive treatment for patients with inoperable non-small cell lung cancer (NSCLC). However, whether it i...

